Carl Zeiss Meditec AG (XSWX:AFX) Change In Receivables: CHF0 Mil (TTM As of Dec. 2025)


XSWX:AFX Carl Zeiss Meditec AG XSWX:AFX
70 GF Score
Price CHF26.30
GF Value CHF314.66
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Carl Zeiss Meditec AG Change In Receivables?

Carl Zeiss Meditec AG XSWX:AFX 70 Change In Receivables is CHF0 Mil as of Dec. 2025. GuruFocus rates XSWX:AFX with a GF Score™ of 70/100 and a GF Value™ of CHF314.66 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Carl Zeiss Meditec AG's change in receivables for the quarter that ended in Dec. 2025 was CHF0 Mil. It means Carl Zeiss Meditec AG's Accounts Receivable stayed the same from Sep. 2025 to Dec. 2025 .

Carl Zeiss Meditec AG's change in receivables for the fiscal year that ended in Sep. 2025 was CHF-99 Mil. It means Carl Zeiss Meditec AG's Accounts Receivable increased by CHF99 Mil from Sep. 2024 to Sep. 2025 .

Carl Zeiss Meditec AG's Accounts Receivable for the quarter that ended in Dec. 2025 was CHF0 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Carl Zeiss Meditec AG's Days Sales Outstanding for the three months ended in Dec. 2025 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Carl Zeiss Meditec AG's liquidation value for the three months ended in Dec. 2025 was CHF0 Mil.

Carl Zeiss Meditec AG  (XSWX:AFX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Carl Zeiss Meditec AG's Days Sales Outstanding for the quarter that ended in Dec. 2025 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/435.776*91
=0.00

2. In Ben Graham's calculation of liquidation value, Carl Zeiss Meditec AG's accounts receivable are only considered to be worth 75% of book value:

Carl Zeiss Meditec AG's liquidation value for the quarter that ended in Dec. 2025 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0-0+0.75 * 0+0.5 * 0
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carl Zeiss Meditec AG Change In Receivables Related Terms

Carl Zeiss Meditec AG Change In Receivables Historical Data

* Premium members only.

The historical data trend for Carl Zeiss Meditec AG's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carl Zeiss Meditec AG Change In Receivables Chart

Carl Zeiss Meditec AG Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -67.42 -71.67 -20.33 20.33 -99.49

Carl Zeiss Meditec AG Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XSWX:AFX
70GF Score
Carl Zeiss Meditec AG XSWX:AFX
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carl Zeiss Meditec AG Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of CHF0 Mil mean?
Carl Zeiss Meditec AG (XSWX:AFX) has a Change In Receivables of CHF0 Mil as of Dec. 2025. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Carl Zeiss Meditec AG and its competitors.
Is Carl Zeiss Meditec AG's Change In Receivables too high?
Carl Zeiss Meditec AG's current Change In Receivables is CHF0 Mil. Overall, Carl Zeiss Meditec AG has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's Change In Receivables compare to ISRG and BDX?
Carl Zeiss Meditec AG's Change In Receivables of CHF0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Medical Devices & Instruments company?
A good Change In Receivables depends on the Medical Devices & Instruments industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Carl Zeiss Meditec AG and its competitors. Carl Zeiss Meditec AG's current Change In Receivables is CHF0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG (XSWX:AFX) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF314.66, compared to a current price of CHF26.30 — trading 91.6% below its estimated fair value. The current Change In Receivables is CHF0 Mil. Carl Zeiss Meditec AG's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Carl Zeiss Meditec AG (XSWX:AFX), the current Change In Receivables is CHF0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carl Zeiss Meditec AG (XSWX:AFX) Overvalued in 2026?

Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued. The current stock price of CHF26.30 is trading 91.6% below its estimated GF Value™ of CHF314.66. GuruFocus considers Carl Zeiss Meditec AG to be Significantly Undervalued.

Key valuation signals for XSWX:AFX:

  • Change In Receivables: CHF0 Mil
  • GF Value™: CHF314.66 vs. price of CHF26.30 (91.6% below fair value)
  • GF Score™: 70/100 with 3 warning signs

No single metric tells the full story. See the XSWX:AFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Carl Zeiss Meditec AG Business Description

Address Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
70GF Score

Get the complete analysis for XSWX:AFX

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF26.30
Price
CHF314.66
GF Value